Tinavi Medical TechnologiesLtd Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jin Xu

Algemeen directeur

CN¥1.3m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	5.6yrs

Recente managementupdates

Recent updates

What Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) 60% Share Price Gain Is Not Telling You

Oct 09

Is Tinavi Medical TechnologiesLtd (SHSE:688277) A Risky Investment?

Jun 14

More Unpleasant Surprises Could Be In Store For Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Shares After Tumbling 26%

Apr 21

There's Reason For Concern Over Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Massive 25% Price Jump

Mar 06

Health Check: How Prudently Does Tinavi Medical TechnologiesLtd (SHSE:688277) Use Debt?

Feb 27

CEO

Jin Xu (50 yo)

no data

Tenure

CN¥1,332,300

Compensatie

Mr. Jin Xu serves as the General Manager and Director of TINAVI Medical Technologies Co., Ltd.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jin Xu	GM & Director	no data	CN¥1.33m	0.071% CN¥ 3.4m
Min Ma	President & Director	no data	CN¥4.82m	geen gegevens
Yang Xu	Independent Director	1.2yrs	CN¥40.00k	geen gegevens
Ruijun Zhang	Independent Director	1.2yrs	CN¥40.00k	geen gegevens
Changjiu Dai	Independent Director	5.6yrs	CN¥90.00k	geen gegevens
Dequan Zhu	Director	14.1yrs	geen gegevens	geen gegevens
Zhi Xiao	Director	6yrs	geen gegevens	geen gegevens
Songgen Zhang	Chairman	14.1yrs	CN¥1.34m	16.84% CN¥ 813.4m
Binbin Wang	Director	8.8yrs	geen gegevens	0.024% CN¥ 1.2m
Guangzhi Wang	Independent Director	5.6yrs	CN¥90.00k	geen gegevens
Zhaoqi Zhu	Supervisor	4.2yrs	geen gegevens	geen gegevens
Chi Yung Lee	Independent Director	1.2yrs	CN¥40.00k	geen gegevens

5.6yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 688277 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).

Tinavi Medical TechnologiesLtd Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Tinavi Medical Technologies Co.,Ltd., Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.072 loss per share (vs CN¥0.082 loss in 3Q 2023)

What Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) 60% Share Price Gain Is Not Telling You

New minor risk - Share price stability

Tinavi Medical Technologies Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.085 loss per share (vs CN¥0.093 loss in 2Q 2023)

Tinavi Medical Technologies Co.,Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Is Tinavi Medical TechnologiesLtd (SHSE:688277) A Risky Investment?

Tinavi Medical Technologies Co.,Ltd., Annual General Meeting, Jun 27, 2024

Full year 2023 earnings released: CN¥0.35 loss per share (vs CN¥0.26 loss in FY 2022)

More Unpleasant Surprises Could Be In Store For Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Shares After Tumbling 26%

Tinavi Medical Technologies Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

There's Reason For Concern Over Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Massive 25% Price Jump

Full year 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.26 loss in FY 2022)

Health Check: How Prudently Does Tinavi Medical TechnologiesLtd (SHSE:688277) Use Debt?

Third quarter 2023 earnings released: CN¥0.082 loss per share (vs CN¥0.088 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.093 loss per share (vs CN¥0.039 loss in 2Q 2022)

TINAVI Medical Technologies Co., Ltd. to Report Q2, 2023 Results on Aug 23, 2023

Full year 2022 earnings released: CN¥0.26 loss per share (vs CN¥0.19 loss in FY 2021)

Full year 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.19 loss in FY 2021)

Beijing Huilin Oriental Technology Partnership Enterprise (Limited Partnership) and Wang Binbin entered into an agreement to acquire 12% stake in Beijing Shuimu Dongfang Medical Robotics Technology Innovation Center Co., Ltd. from TINAVI Medical Technologies Co., Ltd. (SHSE:688277).

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.088 loss per share (vs CN¥0.06 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.039 loss per share (vs CN¥0.031 loss in 2Q 2021)

First quarter 2022 earnings released: CN¥0.07 loss per share (vs CN¥0.06 loss in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: CN¥0.06 loss per share (vs CN¥0.04 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.031 loss per share (vs CN¥0.049 loss in 2Q 2020)

TINAVI Medical Technologies Co., Ltd. announced that it expects to receive CNY 1.34 billion in funding

First quarter 2021 earnings released: CN¥0.06 loss per share (vs CN¥0.04 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.14 loss per share (vs CN¥0.08 loss in FY 2019)

New 90-day low: CN¥34.82

New 90-day low: CN¥45.92

New 90-day low: CN¥55.62

TINAVI Medical Technologies Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd